Provided by Tiger Trade Technology Pte. Ltd.

Salarius Pharmaceuticals Inc

0.8400
0.0000
Volume:- -
Turnover:4.69M
Market Cap:5.36M
PE:-0.02
High:0.8400
Open:0.8400
Low:0.8400
Close:0.8400
52wk High:108.00
52wk Low:0.5148
Shares:6.38M
Float Shares:6.34M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-39.1909
EPS(LYR):-86.9214
ROE:-139.55%
ROA:-69.91%
PB:1.26
PE(LYR):-0.01

Loading ...

Company Profile

Company Name:
Salarius Pharmaceuticals Inc
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
- -
Office Location:
- -
Zip Code:
- -
Phone:
- -
Fax:
- -
Introduction:
Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds and Cancer Prevention and Research Institute of Texas for product development activities. The company is headquartered in Houston, Texas.